Boston Scientific Corporation announced its third quarter 2026 financial results, reporting net sales of $5.138 billion, a 1.5 percent increase compared to the prior year period. GAAP net income attributable to common stockholders was $582 million, or $0.40 per share, while adjusted EPS reached $0.73.
Generated third quarter 2026 net sales of $5.138 billion, up 1.5 percent reported, operational, and organic year-over-year.
Reported GAAP net income attributable to common stockholders of $582 million, or $0.40 per share, and adjusted EPS of $0.73.
Estimated full-year 2026 organic net sales growth of approximately 3.75 percent and adjusted EPS of $3.16 to $3.18.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Boston Scientific's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$20.07B
+19.9%
$1.94
+55.2%
14.4%
FY2024
$16.75B
+17.6%
$1.25
+16.8%
11.1%
FY2023
$14.24B
+12.3%
$1.07
+137.8%
11.0%
FY2022
$12.68B
+6.7%
$0.45
-34.8%
5.1%
FY2021
$11.89B
+19.9%
$0.69
—
8.3%
Frequently asked questions
When is Boston Scientific's next earnings date?
Boston Scientific has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Boston Scientific earn last quarter?
For the quarter ended Sep 2026, Boston Scientific reported diluted EPS of $0.40 (-21.6% year over year) on revenue of $5.14B (+1.4%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.